Loss of heterozygosity (LOH) occurs commonly in cancers causing disruption of tumor suppressor genes and promoting tumor progression. BALB/c-Trp53+/− mice are a model of Li-Fraumeni syndrome, exhibiting a high frequency of mammary tumors and other tumor types seen in patients. However, the frequency of mammary tumors and LOH differs among strains of Trp53+/− mice, with mammary tumors occurring only on a BALB/c genetic background and showing a high frequency of LOH, whereas Trp53+/− mice on a 129/Sv or (C57BL/6 × 129/Sv) mixed background have a very low frequency of mammary tumors and show LOH for Trp53 in only ∼50% of tumors. We have performed studies on tumors from Trp53+/− mice of several genetic backgrounds to examine the mechanism of LO...
BALB/c mice are predisposed to developing spontaneous mammary tumors, which are further increased in...
p53 is one of the most frequently mutated genes in mammary carcinomas (MCs). To detect tumor suppres...
Background: Here we present the first paired-end sequencing of tumors from genetically engineered mo...
Loss of heterozygosity (LOH) occurs commonly in cancers causing disruption of tumor suppressor genes...
Loss of heterozygosity (LOH) occurs commonly in cancers causing disruption of tumor suppressor genes...
Breast cancer is the most frequent tumor type in women in the US. Breast cancer is also the most pre...
Breast cancer is the most frequent tumor type in women in the US. Breast cancer is also the most pre...
Breast cancer is the most frequent tumor type among women in the United States and in individuals wi...
Loss of p53 function can lead to a variety of cancers, including breast cancer. Mice heterozygous fo...
Breast cancer is the most common tumor among women with inherited variants in the TP53 tumor suppres...
Loss of p53 function can lead to a variety of cancers, including breast cancer. Mice heterozygous fo...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
We engineered a mammary-specific knockout model for Brca1 deficiency that also lacks the majority of...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
Genetic alterations that cooperate with TP53 mutation in breast cancer (BC) are largely unknown. Usi...
BALB/c mice are predisposed to developing spontaneous mammary tumors, which are further increased in...
p53 is one of the most frequently mutated genes in mammary carcinomas (MCs). To detect tumor suppres...
Background: Here we present the first paired-end sequencing of tumors from genetically engineered mo...
Loss of heterozygosity (LOH) occurs commonly in cancers causing disruption of tumor suppressor genes...
Loss of heterozygosity (LOH) occurs commonly in cancers causing disruption of tumor suppressor genes...
Breast cancer is the most frequent tumor type in women in the US. Breast cancer is also the most pre...
Breast cancer is the most frequent tumor type in women in the US. Breast cancer is also the most pre...
Breast cancer is the most frequent tumor type among women in the United States and in individuals wi...
Loss of p53 function can lead to a variety of cancers, including breast cancer. Mice heterozygous fo...
Breast cancer is the most common tumor among women with inherited variants in the TP53 tumor suppres...
Loss of p53 function can lead to a variety of cancers, including breast cancer. Mice heterozygous fo...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
We engineered a mammary-specific knockout model for Brca1 deficiency that also lacks the majority of...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
Genetic alterations that cooperate with TP53 mutation in breast cancer (BC) are largely unknown. Usi...
BALB/c mice are predisposed to developing spontaneous mammary tumors, which are further increased in...
p53 is one of the most frequently mutated genes in mammary carcinomas (MCs). To detect tumor suppres...
Background: Here we present the first paired-end sequencing of tumors from genetically engineered mo...